Safinamide
CAS: 133865-89-1
Ref. 3D-FS60428
5g | Discontinued | ||
10g | Discontinued | ||
25g | Discontinued | ||
50g | Discontinued | ||
100g | Discontinued |
Product Information
- (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propionamide
- (2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamide
- (2S)-2-[[[4-[(3-Fluorophenyl)methoxy]phenyl]methyl]amino]propanamide
- (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide
- (S)-2-[[[4-[(3-Fluorophenyl)methoxy]phenyl]methyl]amino]propanamide
- Emd 1195686
- Fce 26743
- N~2~-{4-[(3-fluorobenzyl)oxy]benzyl}-L-alaninamide
- Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-
- Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (S)-
- See more synonyms
(S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propionamide (FPP) is a potent and selective inhibitor of enzyme activity. It has been shown to be effective in the treatment of diabetic neuropathy, Parkinson's disease and Alzheimer's disease. FPP inhibits enzymes involved in the synthesis of dopamine, glutamate, and catecholamines. The drug is also able to inhibit neuronal death through its ability to inhibit the release of protein-degrading enzymes. This effect can be attributed to its ability to bind with inhibitor molecules that are involved in the degradation reactions. FPP can be detected in biological samples using liquid chromatography-mass spectrometry (LC-MS/MS).